CN112166121A - 神经生长因子的单克隆抗体及其编码基因和应用 - Google Patents

神经生长因子的单克隆抗体及其编码基因和应用 Download PDF

Info

Publication number
CN112166121A
CN112166121A CN201980026536.1A CN201980026536A CN112166121A CN 112166121 A CN112166121 A CN 112166121A CN 201980026536 A CN201980026536 A CN 201980026536A CN 112166121 A CN112166121 A CN 112166121A
Authority
CN
China
Prior art keywords
growth factor
nerve growth
monoclonal antibody
antibody
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980026536.1A
Other languages
English (en)
Other versions
CN112166121B (zh
Inventor
王忠民
李百勇
夏瑜
张鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akeso Pharmaceuticals Inc
Original Assignee
Akeso Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akeso Biopharma Inc filed Critical Akeso Biopharma Inc
Publication of CN112166121A publication Critical patent/CN112166121A/zh
Application granted granted Critical
Publication of CN112166121B publication Critical patent/CN112166121B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明公开了神经生长因子的单克隆抗体及其编码基因和应用。本发明神经生长因子的单克隆抗体包括重链和轻链，重链包括重链恒定区和重链可变区，轻链包括轻链恒定区和轻链可变区，重链可变区包含三个互补决定区HCDR1、HCDR2和HCDR3；轻链可变区包含三个互补决定区LCDR1、LCDR2和LCDR3。本发明神经生长因子的单克隆抗体能特异性地与神经生长因子结合，可用于检测神经生长因子的存在和/或水平，以及制备抑制TF‑1细胞的神经生长因子依赖性增殖的药物、制备治疗或预防神经性疼痛、慢性疼痛、炎性疼痛中的至少一种的药物，具有良好的应用前景和市场价值。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201980026536.1A 2018-04-17 2019-04-10 神经生长因子的单克隆抗体及其编码基因和应用 Active CN112166121B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810344670.3A CN108623687A (zh) 2018-04-17 2018-04-17 神经生长因子的单克隆抗体及其编码基因和应用
CN2018103446703 2018-04-17
CN2018113200061 2018-11-07
CN201811320006.1A CN109553683A (zh) 2018-04-17 2018-11-07 神经生长因子的单克隆抗体及其编码基因和应用
PCT/CN2019/082107 WO2019201133A1 (zh) 2018-04-17 2019-04-10 神经生长因子的单克隆抗体及其编码基因和应用

Publications (2)

Publication Number Publication Date
CN112166121A true CN112166121A (zh) 2021-01-01
CN112166121B CN112166121B (zh) 2022-11-22

Family

ID=63705267

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201810344670.3A Pending CN108623687A (zh) 2018-04-17 2018-04-17 神经生长因子的单克隆抗体及其编码基因和应用
CN201811320006.1A Pending CN109553683A (zh) 2018-04-17 2018-11-07 神经生长因子的单克隆抗体及其编码基因和应用
CN201980026536.1A Active CN112166121B (zh) 2018-04-17 2019-04-10 神经生长因子的单克隆抗体及其编码基因和应用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201810344670.3A Pending CN108623687A (zh) 2018-04-17 2018-04-17 神经生长因子的单克隆抗体及其编码基因和应用
CN201811320006.1A Pending CN109553683A (zh) 2018-04-17 2018-11-07 神经生长因子的单克隆抗体及其编码基因和应用

Country Status (15)

Country Link
US (2) US11680095B2 (zh)
EP (1) EP3783021A4 (zh)
JP (1) JP7499228B2 (zh)
KR (1) KR20200143471A (zh)
CN (3) CN108623687A (zh)
AU (1) AU2019254934A1 (zh)
BR (1) BR112020021256A2 (zh)
CA (1) CA3097414A1 (zh)
EA (1) EA202092491A1 (zh)
IL (1) IL277982A (zh)
MX (1) MX2020010863A (zh)
PH (1) PH12020551678A1 (zh)
SG (1) SG11202010150PA (zh)
WO (1) WO2019201133A1 (zh)
ZA (1) ZA202006317B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113444176A (zh) * 2021-06-02 2021-09-28 武汉人福创新药物研发中心有限公司 Ngf的抗体及其应用
CN116836276A (zh) * 2023-07-28 2023-10-03 艾可泰科(浙江)控股有限公司 一种用于修复膝关节损伤的干细胞制剂及其制备工艺

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623687A (zh) * 2018-04-17 2018-10-09 中山康方生物医药有限公司 神经生长因子的单克隆抗体及其编码基因和应用
CN110684106B (zh) * 2019-09-30 2021-02-02 达石药业(广东)有限公司 一种靶向神经生长因子的单克隆抗体及其应用
CN117186219A (zh) * 2020-04-17 2023-12-08 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN113527483B (zh) * 2020-04-17 2023-09-22 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
EP4157881A1 (en) * 2020-05-27 2023-04-05 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
CN114470189B (zh) * 2020-11-12 2024-01-16 达石药业(广东)有限公司 Ngf抗体在cipn性疼痛中的应用
WO2023004784A1 (zh) 2021-07-30 2023-02-02 成都优洛生物科技有限公司 一种重组cho细胞、其构建方法、利用其的检测系统和方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1849138A (zh) * 2003-07-15 2006-10-18 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
CN102459337A (zh) * 2009-05-04 2012-05-16 雅培研究有限责任公司 具有增强的体内稳定性的抗神经生长因子(ngf)抗体
CN104910274A (zh) * 2015-02-12 2015-09-16 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NZ587852A (en) * 2002-12-24 2012-02-24 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
AU2011201157C1 (en) * 2002-12-24 2017-09-07 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
PL1732949T3 (pl) 2004-04-07 2010-06-30 Rinat Neuroscience Corp Sposoby leczenia nowotworowego bólu kości przez podawanie antagonisty czynnika wzrostu nerwów
AU2012201465A1 (en) * 2005-06-07 2012-04-05 Abbott Research B.V Molecules that are able to inhibit the binding between NGF and the TrkA receptor as analgesics with prolonged effect
ME02239B (me) 2007-08-10 2015-04-30 Regeneron Pharma Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta
AU2011336470B8 (en) * 2010-12-01 2017-09-14 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
CN108623687A (zh) * 2018-04-17 2018-10-09 中山康方生物医药有限公司 神经生长因子的单克隆抗体及其编码基因和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1849138A (zh) * 2003-07-15 2006-10-18 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
CN102459337A (zh) * 2009-05-04 2012-05-16 雅培研究有限责任公司 具有增强的体内稳定性的抗神经生长因子(ngf)抗体
CN104910274A (zh) * 2015-02-12 2015-09-16 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113444176A (zh) * 2021-06-02 2021-09-28 武汉人福创新药物研发中心有限公司 Ngf的抗体及其应用
CN116836276A (zh) * 2023-07-28 2023-10-03 艾可泰科(浙江)控股有限公司 一种用于修复膝关节损伤的干细胞制剂及其制备工艺
CN116836276B (zh) * 2023-07-28 2023-12-08 艾可泰科(浙江)控股有限公司 一种用于修复膝关节损伤的干细胞制剂及其制备工艺

Also Published As

Publication number Publication date
WO2019201133A1 (zh) 2019-10-24
CA3097414A1 (en) 2019-10-24
KR20200143471A (ko) 2020-12-23
US20240025983A1 (en) 2024-01-25
JP2021521881A (ja) 2021-08-30
CN109553683A (zh) 2019-04-02
US20210155683A1 (en) 2021-05-27
EP3783021A4 (en) 2022-03-02
EP3783021A1 (en) 2021-02-24
EA202092491A1 (ru) 2021-02-09
SG11202010150PA (en) 2020-11-27
JP7499228B2 (ja) 2024-06-13
BR112020021256A2 (pt) 2021-02-02
IL277982A (en) 2020-11-30
AU2019254934A1 (en) 2020-11-19
CN108623687A (zh) 2018-10-09
ZA202006317B (en) 2024-01-31
CN112166121B (zh) 2022-11-22
US11680095B2 (en) 2023-06-20
MX2020010863A (es) 2021-01-29
PH12020551678A1 (en) 2021-06-07

Similar Documents

Publication Publication Date Title
CN112166121B (zh) 神经生长因子的单克隆抗体及其编码基因和应用
WO2017071625A1 (zh) 一种抗pd-1单克隆抗体、其药物组合物及其用途
CN106687479B (zh) 抗ctla4的单克隆抗体或其抗原结合片段、药物组合物及用途
CN110366560B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
US20200031934A1 (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
US11402383B2 (en) Nucleic acid encoding PCSK9 antibody
CN111902428A (zh) 一种双特异性抗体及其用途
CA2915386A1 (en) Cb1 receptor antigen-binding proteins and uses thereof
CN111196849B (zh) 抗硬骨素抗体、其抗原结合片段及其医药用途
WO2014016702A2 (en) Humanized forms of monoclonal antibodies to human gnrh receptor
TWI685504B (zh) 抗gitr抗體、其抗原結合片段及其醫藥用途
US20220064272A1 (en) Anti-tauc3 antibodies and uses thereof
CA3152860A1 (en) Anti-tfpi monoclonal antibodies
EA044828B1 (ru) Моноклональное антитело против фактора роста нервов, кодирующий его ген и его применение
CN112079922B (zh) 抗人p40蛋白域抗体及其用途
US20220411523A1 (en) Molecule capable of binding to human 4-1bb and its application thereof
CN118206657A (zh) 一种半乳糖凝集素-3的抗体及其应用
KR20240017071A (ko) 항-masp-2 항체 및 이의 용도
CN116574189A (zh) 针对人il-36r和/或人il-1r3的多种抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant